Metabolic Syndrome and Contrast Induced Nephropathy

N/ACompletedNCT02192372

Ankara University599 enrolled

Overview

Prevention of contrast induced nephropathy after interventional cardiologic procedures deserves close interest because of its association with prolonged hospitalization, increased cost and increased in hospital and long term mortality rates. An observational prospective cohort study was designed to determine whether metabolic syndrome predicts the development of contrast induced nephropathy after elective percutaneous coronary intervention.

Study Type

OBSERVATIONAL

Enrollment

599

Conditions

Contrast Induced Nephropathy Metabolic Syndrome

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients must be scheduled for elective percutaneous coronary intervention Clinical diagnosis of metabolic syndrome Patients must give informed consent Exclusion Criteria: Acute coronary events Acute renal failure End stage renal failure requiring hemodialysis Contrast allergy and exposure to nephrotoxic agent within 1 week before percutaneous coronary intervention Exposure to contrast agent within 1 week before the procedure.

Locations (1)

Ankara University School Of Medicine, Department of Cardiology

Ankara, Turkey (Türkiye)

Outcomes

Primary Outcomes

Contrast induced nephropathy

Contrast induced nephropathy was defined as an increase in serum creatinine of \>25% or \>0.5 mg/dl above the baseline value 24 or 48 hours after angiography.

Time frame: 24-48 hours after the percutaneous coronary intervention

Secondary Outcomes

glomerular filtration rate

Glomerular filtration rate was estimated using the Cockcroft-Gault formula: (140-age) x weight (kg)/ serum creatinine (mg/dl) x 72 (x 0.85 for females)

Time frame: 48 hours after the percutaneous coronary intervention

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.